2014
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study
Lynch TJ, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP, Investigators O. Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. Journal Of Thoracic Oncology 2014, 9: 1332-1339. PMID: 25122429, DOI: 10.1097/jto.0000000000000257.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug Therapy, CombinationEuropeFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedProspective StudiesSurvival RateTime FactorsTreatment OutcomeUnited StatesVascular Endothelial Growth Factor AConceptsTrial of bevacizumabObservational cohort studyCell lung cancerCohort studyLung cancerARIES observational cohort studyBevacizumab-associated adverse eventsMedian progression-free survivalProspective observational cohort studyReal-world patient populationRecombinant humanized monoclonal antibodyFirst-line bevacizumabProtocol-defined treatmentMedian overall survivalProgression-free survivalEffectiveness of bevacizumabCommunity-based populationHumanized monoclonal antibodyVascular endothelial growth factorEndothelial growth factorSquamous histologyAdvanced NSCLCChemotherapy regimenMetastatic NSCLCAdverse events
2010
Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS).
Kumar P, Fischbach N, Brahmer J, Spigel D, Beatty S, Teng S, Flick E, Sing A, Lynch T. Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). Journal Of Clinical Oncology 2010, 28: 7619-7619. DOI: 10.1200/jco.2010.28.15_suppl.7619.Peer-Reviewed Original Research
2009
9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)
Jahanzeb M, Fischbach N, Kosty M, Kumar P, Spigel D, Wozniak A, Teng S, Wang L, Sing A, Lynch T. 9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS). European Journal Of Cancer Supplements 2009, 7: 507. DOI: 10.1016/s1359-6349(09)71719-7.Peer-Reviewed Original ResearchPreliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS)
Fischbach N, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). Journal Of Clinical Oncology 2009, 27: 8040-8040. DOI: 10.1200/jco.2009.27.15_suppl.8040.Peer-Reviewed Original ResearchNon-small cell lung cancerObservational cohort studyAdverse eventsClinical outcomesNSCLC ptsAdvanced non-small cell lung cancerARIES observational cohort studyMedian f/uAnti-VEGF monoclonal antibodyKey safety outcomeProtocol-specified treatmentSafety of bevacizumabCarboplatin/paclitaxelSerious adverse eventsPhase III trialsEffectiveness of bevacizumabCell lung cancerSubpopulation of patientsCohort sizePoor PSBrain metastasesChemotherapy regimenBaseline characteristicsCohort studyIII trials
2008
Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS)
Lynch T, Brahmer J, Fischbach N, Garst J, Kumar P, Spigel D, Teng S, Vidaver R, Wang L, Navarro W. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS). Journal Of Clinical Oncology 2008, 26: 8077-8077. DOI: 10.1200/jco.2008.26.15_suppl.8077.Peer-Reviewed Original ResearchNon-small cell lung cancerObservational cohort studyCell lung cancerCohort studyTreatment patternsLung cancerSafety outcomesCancer